Emergent BioSolutions (EBS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Apr, 2026Executive summary
Annual meeting of stockholders scheduled for April 29, 2026, at 9 a.m. Eastern Time.
Only shareholders of record as of March 6, 2026, are eligible to vote at the meeting.
Shareholders are encouraged to review the proxy statement and related SEC filings for important information.
Voting matters and shareholder proposals
Eligible shareholders can vote even if not attending the virtual meeting by submitting a proxy vote.
Voting instructions will be sent via E*TRADE email, and support is available for account access issues.
Shareholder rights and capital structure
Only vested shareholders as of the record date are entitled to participate in voting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Emergent BioSolutions
- Q2 2026 saw strong MCM growth but a $191.3M NARCAN® impairment drove a $180.2M net loss.EBS
Q2 2026 - Turnaround delivers strong EBITDA, innovation, and global growth in biodefense and opioid solutions.EBS
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Turnaround delivers strong Q1 2026 results, with growth from innovation and global expansion.EBS
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue beat guidance but fell 30% year-over-year; liquidity and outlook remain strong.EBS
Q1 2026 - Strong financial turnaround, all proposals approved, and growth-focused strategies outlined.EBS
AGM 2026 - Annual meeting on April 29, 2026, with proxy voting available for eligible shareholders.EBS
Proxy filing - Virtual annual meeting set for April 29, 2026, with proxy materials filed.EBS
Proxy filing - Approval is sought for a new equity plan to support ongoing turnaround and talent retention.EBS
Proxy filing - Q3 2024 net income jumped 144% and adjusted EBITDA rose 432% as guidance was raised.EBS
Q3 2024